The pharmacological treatment of eating disorders: new guidelines and gender-specific aspects

Author/s
Hubertus Himmerich, Cheyenne Lee, Victoria Burmester, Dasha Nicholls, Janet Treasure
Citation
Focus Issue 6: Eating disorders
CEPiP.2024.1.214-221
Abstract

Even though psychopharmacology has made substantial progress in many areas of psychiatry since the discovery of antipsychotics and antidepressants in the 1950s, the evidence base for pharmacological treatments in the field of eating disorders has been lagging. The World Federation of Societies of Biological Psychiatry guidelines update 2023 on the pharmacological treatment of eating disorders provides a comprehensive summary of pharmacological studies and recommendations for anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), avoidant restrictive food intake disorder, pica and rumination disorder. However, there are very few studies in adolescents, implying that evidence-based recommendations in this population are difficult to make. Gender-specific aspects have also been addressed in the guidelines update, such as the small number of male patients included in pharmacological studies in AN and BN. Furthermore, the guidelines recommend against the treatment of female AN patients with testosterone, mention that topiramate for the treatment of BN and BED is contraindicated during pregnancy and that fluoxetine and its metabolite norfluoxetine inhibit the metabolism of the anti-breast cancer prodrug tamoxifen to its active metabolite endoxifen.

Keywords:  eating disorder, anorexia nervosa, bulimia nervosa, binge eating disorder, avoidant restrictive food intake disorder, pharmacological treatment, gender

Cite as: Cutting Edge Psychiatry in Practice 2025, 6(1):214-221; https://doi.org/10.65031/eljt6803

References

  1. Van Deth R, Vandereycken W. Eating Disorders: Clinical Section. In: Berrios G (editor). A History of Psychiatry. London. Routledge (2008). p.593-601.
  2. Russell G. Bulimia nervosa: an ominous variant of anorexia nervosa. Psychological Medicine. 1979;9(3):429-48. https://doi.org/10.1017/s0033291700031974
  3. Stunkard AJ. Eating patterns and obesity. Psychiatric Quarterly. 1959;33(2):284-95.          
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5). Arlington, VA. American Psychiatric Association (2013). https://doi.org/10.1007/springerreference_179660
  5. World Health Organisation (WHO). International Classification of Diseases 11th Revision 2021. Available from: https://icd.who.int.     
  6. Delay J, Deniker P. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. Journal of Clinical and Experimental Psychopathology. 1955;16(2):104-12. 
  7. Thuillier J. Les dix ans qui ont chang. la folie. Paris. Robert Laffont (1980).       
  8. Steinberg H, Himmerich H. Roland Kuhn - 100th Birthday of an innovator of clinical psychopharmacology. Psychopharmacology Bulletin. 2012;45(1):48. https://doi.org/10.64719/pb.4061
  9. Himmerich H, Treasure J. Psychopharmacological advances in eating disorders. Expert Review of Clinical Pharmacology. 2018;11(1):95-108. https://doi.org/10.1080/17512433.2018.1383895
  10. Freeman C, Hampson M. Fluoxetine as a treatment for bulimia nervosa. International Journal of Obesity. 1987;11:171-7.   
  11. Eddy KT, Tabri N, Thomas JJ, Murray HB, Keshaviah A, Hastings E, et al. Recovery from anorexia nervosa and bulimia nervosa at 22-year follow-up. The Journal of Clinical Psychiatry. 2017;78(2):17085. https://doi.org/10.4088/jcp.15m10393
  12. Wentz E, Gillberg C, Gillberg IC, Röstam M. Ten-year follow-up of adolescent-onset anorexia nervosa: psychiatric disorders and overall functioning scales. The Journal of Child Psychology and Psychiatry and Allied Disciplines. 2001;42(5):613-22. https://doi.org/10.1111/1469-7610.00757
  13. Herpertz‐Dahlmann B, Dempfle A, Egberts KM, Kappel V, Konrad K, Vloet JA, et al. Outcome of childhood anorexia nervosa - the results of a five‐to ten‐year follow‐up study. International Journal of Eating Disorders. 2018;51(4):295-304. https://doi.org/10.1002/eat.22840
  14. Aigner M, Treasure J, Kaye W, Kasper S, Disorders WTFOE. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. The World Journal of Biological Psychiatry. 2011;12(6):400-43. https://doi.org/10.3109/15622975.2011.602720
  15. Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Möller H-J, et al. WFSBP guidelines on how to grade treatment evidence for clinical guideline development. The World Journal of Biological Psychiatry. 2019;20(1):2-16. https://doi.org/10.1080/15622975.2018.1557346
  16. Scottish Intercollegiate Guidelines Network (SIGN). Accessed 03 September 2023. Available from: https://www.sign.ac.uk/.                 
  17. Himmerich H, Lewis YD, Conti C, Mutwalli H, Karwautz A, Sjögren JM, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. The World Journal of Biological Psychiatry. 2023:1-64. https://doi.org/10.1080/15622975.2023.2179663
  18. Treasure J. Neuroimaging of eating disorders: commentary. In: Shenton M, Turetsky B, editors. Understanding Neuropsychiatric Disorders: Insights from Neuroimaging. Cambridge. Cambridge University Press (2011). p. 510-6. https://doi.org/10.1017/cbo9780511782091.036
  19. Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? Psychoneuroendocrinology. 2007;32(4):402-6. https://doi.org/10.1016/j.psyneuen.2007.02.005
  20. Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry. 2008;165(10):1281-8. https://doi.org/10.1176/appi.ajp.2008.07121900
  21. Attia E, Kaplan A, Walsh B, Gershkovich M, Yilmaz Z, Musante D, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychological Medicine. 2011;41(10):2177-82. https://doi.org/10.1017/s0033291711000390
  22. Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, Schreyer C, et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. American Journal of Psychiatry. 2019;176(6):449-56. https://doi.org/10.1176/appi.ajp.2018.18101125
  23. Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. Journal of Child and Adolescent Psychopharmacology. 2011;21(3):207-12. https://doi.org/10.1089/cap.2010.0139
  24. Couturier J, Isserlin L, Norris M, Spettigue W, Brouwers M, Kimber M, et al. Canadian practice guidelines for the treatment of children and adolescents with eating disorders. Journal of Eating Disorders. 2020;8:1-80. https://doi.org/10.1186/s40337-020-00307-2
  25. Andries A, Frystyk J, Flyvbjerg A, Støving RK. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. International Journal of Eating Disorders. 2014;47(1):18-23. https://doi.org/10.1002/eat.22173
  26. Andries A, Gram B, Støving RK. Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial. Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity. 2015;20:13-21. https://doi.org/10.1007/s40519-014-0132-5
  27. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo controlled, double-blind trial. Arch Gen Psychiatry. 1992;49:139-47. https://doi.org/10.1001/archpsyc.1992.01820020059008
  28. Goldstein DJ, Wilson MG, Thompson VL, Potvin JH, Rampey AH, Fluoxetine Bulimia Nervosa Research Group. Long-term fluoxetine treatment of bulimia nervosa. The British Journal of Psychiatry. 1995;166(5):660-6. https://doi.org/10.1192/bjp.166.5.660
  29. Walsh BT, Agras WS, Devlin MJ, Fairburn CG, Wilson GT, Kahn C, et al. Fluoxetine for bulimia nervosa following poor response to psychotherapy. American Journal of Psychiatry. 2000;157(8):1332-4. https://doi.org/10.1176/appi.ajp.157.8.1332
  30. Romano SJ, Halmi KA, Sarkar NP, Koke SC, Lee JS. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. American Journal of Psychiatry. 2002;159(1):96-102. https://doi.org/10.1176/appi.ajp.159.1.96
  31. Kotler LA, Devlin MJ, Davies M, Walsh BT. An open trial of fluoxetine for adolescents with bulimia nervosa. Journal of Child and Adolescent Psychopharmacology. 2003;13(3):329-35. https://doi.org/10.1089/104454603322572660
  32. Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, Kamin M, Karim R, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. Journal of Clinical Psychiatry. 2003;64(12):1449-54. https://doi.org/10.4088/jcp.v64n1208
  33. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. Journal of Clinical Psychiatry. 2003;64(11):1335-41. https://doi.org/10.4088/jcp.v64n1109
  34. Nickel C, Tritt K, Muehlbacher M, Pedrosa Gil F, Mitterlehner FO, Kaplan P, et al. Topiramate treatment in bulimia nervosa patients: A randomized, double‐blind, placebo‐controlled trial. International Journal of Eating Disorders. 2005;38(4):295-300. https://doi.org/10.1002/eat.20202
  35. Mula M. Topiramate and cognitive impairment: evidence and clinical implications. Therapeutic Advances in Drug Safety. 2012;3(6):279-89. https://doi.org/10.1177/2042098612455357
  36. McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235-46. https://doi.org/10.1001/jamapsychiatry.2014.2162
  37. McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251-60. https://doi.org/10.1038/npp.2015.275
  38. Guerdjikova AI, Mori N, Blom TJ, Keck Jr PE, Williams SL, Welge JA, et al. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial. Human Psychopharmacology: Clinical and Experimental. 2016;31(5):382-91. https://doi.org/10.1002/hup.2547
  39. Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe bingeeating disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):903-10. https://doi.org/10.1001/jamapsychiatry.2017.1889
  40. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biological Psychiatry. 2007;61(9):1039-48. https://doi.org/10.1016/j.biopsych.2006.08.008
  41. McElroy SL, Arnold LM, Shapira NA, Keck Jr PE, Rosenthal NR, Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. American Journal of Psychiatry. 2003;160(2):255-61. https://doi.org/10.1176/appi.ajp.160.2.255
  42. Claudino AM, Oliveira IRd, Appolinario JC, Cordás TA, Duchesne M, Sichieri R, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. Journal of Clinical Psychiatry. 2007;68(9):1324-32.43. https://doi.org/10.4088/jcp.v68n0901
  43. Gray E, Chen T, Menzel J, Schwartz T, Kaye WH. Mirtazapine and weight gain in avoidant and restrictive food intake disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2018;57(4):288-9. https://doi.org/10.1016/j.jaac.2018.01.011
  44. Naviaux A-F. Management of ARFID (avoidant restrictive food intake disorder) in a 12-year-old on a paediatric ward in a general hospital: use of mirtazapine, partial hospitalisation model and family based therapy. Psychiatria Danubina. 2019;31(suppl 3):421-6. https://doi.org/10.13056/acamh.13655
  45. Naguy A, Roshdy R, Al-Mutairi A, Alwetayan S, Alamiri B. Mirtazapine improved eating patterns in avoidant/restrictive food intake disorder. American Journal of Therapeutics. 2023;30(2):173-5. https://doi.org/10.1097/mjt.0000000000001338
  46. Choure J, Quinn K, Franco K. Baking-soda pica in an adolescent patient. Psychosomatics. 2006;47(6):531-2. https://doi.org/10.1176/appi.psy.47.6.531
  47. Upadhyaya SK, Sharma A. Onset of obsessive compulsive disorder in pregnancy with pica as the sole manifestation. Indian Journal of Psychological Medicine. 2012;34(3):276-8. https://doi.org/10.4103/0253-7176.106030
  48. Ikeda M, Shigenobu K, Fukuhara R, Hokoishi K, Maki N, Nebu A, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dementia and Geriatric Cognitive Disorders. 2004;17(3):117-21. https://doi.org/10.1159/000076343
  49. Kanamori T, Kaneko Y, Yamada K, Suzuki M. Successful combination therapy of trazodone and fluvoxamine for pica in Alzheimer's disease: a case report. Frontiers in Psychiatry. 2021;12:704847. https://doi.org/10.3389/fpsyt.2021.704847
  50. Lee H, Rhee PL, Park EH, Kim JH, Son HJ, Kim JJ, et al. Clinical outcome of rumination syndrome in adults without psychiatric illness: a prospective study. Journal of Gastroenterology and Hepatology. 2007;22(11):1741-7. https://doi.org/10.1111/j.1440-1746.2006.04617.x
  51. Pauwels A, Broers C, Van Houtte B, Rommel N, Vanuytsel T, Tack J. A randomized double-blind, placebo-controlled, cross-over study using baclofen in the treatment of rumination syndrome. American Journal of Gastroenterology. 2018;113(1):97-104. https://doi.org/10.1038/ajg.2017.441
  52. Sil.n Y, Keski-Rahkonen A. Worldwide prevalence of DSM-5 eating disorders among young people. Current Opinion in Psychiatry. 2022;35(6):362-71. https://doi.org/10.1097/yco.0000000000000818
  53. Dinkler L, Bryant-Waugh R. Assessment of avoidant restrictive food intake disorder, pica and rumination disorder: interview and questionnaire measures. Current Opinion in Psychiatry. 2021;34(6):532-42. https://doi.org/10.1097/yco.0000000000000736
  54. Zadeh P, Etheridge L. Should teenage girls with anorexia nervosa be offered oestrogen treatment to reduce later risk of osteoporosis? Archives of Disease in Childhood. 2020;105(8):798-802. https://doi.org/10.1136/archdischild-2019-318571
  55. Kimball A, Schorr M, Meenaghan E, Bachmann KN, Eddy KT, Misra M, et al. A randomized placebo-controlled trial of low-dose testosterone therapy in women with anorexia nervosa. The Journal of Clinical Endocrinology and Metabolism. 2019;104(10):4347-55. https://doi.org/10.1210/js.2019-mon-225
  56. Russell J, Maguire S, Hunt GE, Kesby A, Suraev A, Stuart J, et al. Intranasal oxytocin in the treatment of anorexia nervosa: randomized controlled trial during re-feeding. Psychoneuroendocrinology. 2018;87:83-92. https://doi.org/10.1016/j.psyneuen.2017.10.014
  57. National Institute for Health and Care Excellence (NICE). Eating disorders: recognition and treatment. NICE guideline [NG69] 2017. Updated 16 December 2020. Accessed 6 October 2023. Available from: https://www.nice.org.uk/guidance/ng69/chapter/ Recommendations#identification-and-assessment. https://doi.org/10.24292/01.mf.0120.14
  58. Himmerich H, Kan C, Au K, Treasure J. Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences. Pharmacology and Therapeutics. 2021;217:107667. https://doi.org/10.1016/j.pharmthera.2020.107667